Are you Dr. Ahmed?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 45 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-794-4902- Is this information wrong?
Summary
- Dr. Sairah Ahmed, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Arizona, and Alabama. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
- University of ConnecticutResidency, Internal Medicine, 2003 - 2006
- Khyber Medical CollegeClass of 2000
Certifications & Licensure
- FL State Medical License 2021 - Present
- WA State Medical License 2023 - 2026
- OK State Medical License 2020 - 2025
- TX State Medical License 2011 - 2025
- AZ State Medical License 2023 - 2024
- AL State Medical License 2023 - 2024
- TN State Medical License 2023 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) Start of enrollment: 2015 May 22
- Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Start of enrollment: 2021 Sep 08
Publications & Presentations
PubMed
- Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.Sairah Ahmed, Qaiser Bashir, Roland L Bassett Jr, Fauzia Ullah, Fleur Aung, Benigno C Valdez, Amin M Alousi, Chitra Hosing, Partow Kebriaei, Issa Khouri, David Marin, ...> ;American Journal of Hematology. 2024 Apr 1
- Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-ce...Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sairah Ahmed, David B Miklos, Yi Lin, Brian T Hill, Armin Ghobadi, S...> ;American Journal of Hematology. 2024 May 1
- A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.Muhamad Alhaj Moustafa, Jeremy L Ramdial, Athanasios Tsalatsanis, Farhad Khimani, Bhagirathbhai Dholaria, Leyla Bojanini, Taylor Brooks, Jasmine Zain, N Nora Bennani, ...> ;Transplantation and Cellular Therapy. 2024 Feb 29
- Join now to see all
Press Mentions
- What Are the New Weight Loss Drugs Everyone Is Talking About & What’s the Connection Between Weight and Cancer?January 15th, 2023
- Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin LymphomaDecember 13th, 2022
- CAR T Cell Therapy Put Me into Complete Remission After a Non-Hodgkin Lymphoma DiagnosisSeptember 26th, 2022
- Join now to see all
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas